Shanghai Personal Biotechnology Co., Ltd.

Shanghai Personal Biotechnology Co. , Ltd. is a biotechnology firm specializing in genomic and proteomic sequencing services. Their advanced technologies facilitate research in life sciences, offering tailored solutions to a diverse client base.

Founded in 2011, Shanghai Personal Biotechnology Co. , Ltd. operates out of Shanghai, China. The company focuses on genomic and proteomic services and has completed three deals, with the latest funding round being a Series A of USD 3.

10 mn led by Yangtze River Investment Fund Management on June 30, 2018. The CEO, Zikui Sun, leads the firm in its strategic initiatives. Shanghai Personal Biotechnology Co. , Ltd.

offers a comprehensive range of genomic and proteomic sequencing services, using cutting-edge technologies like Illumina NovaSeq and PacBio platforms. Their product offerings include single-cell sequencing, microbiome analysis, and bioinformatics services, catering to academic institutions, healthcare providers, and pharmaceutical companies. They operate both in China and internationally, including markets in North America and Europe. In 2017, Shanghai Personal Biotechnology reported a revenue of USD 7,393,396.

60 and an EBITDA of USD 355,445. 80. The company primarily operates on a B2B basis, providing sequencing services under direct agreements with research institutions and healthcare organizations, with pricing models varying by project complexity. Shanghai Personal Biotechnology Co.

, Ltd. aims to expand its product offerings and market reach, with new services under development projected for launch in late 2022. The firm is targeting expansion into additional markets in Asia and Europe by 2023. The recent Series A funding of USD 3.

10 mn will support these initiatives, enhancing their service capabilities and facilitating further research collaborations.